| Lindsay Jane Mastrine, DO | |
|
600 Somerset Ave, Windber, PA 15963-1331 | |
| (814) 467-3176 | |
| (814) 467-3177 |
| Full Name | Lindsay Jane Mastrine |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 17 Years |
| Location | 600 Somerset Ave, Windber, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013213859 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 2621521 (New York) | Secondary |
| 207V00000X | Obstetrics & Gynecology | OS017709 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Upmc Altoona | Altoona, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Pittsburgh Physicians | 8729990239 | 3721 |
News Archive
Itamar announced today that it signed an agreement with Roche for use of Itamar's EndoPAT device in a clinical phase II study for patients with Peripheral Arterial Disease (PAD) at 80 worldwide medical centers.
According to a new study on Norwegian youth, compared to clear-skinned peers, teens who have bad acne are more than twice as likely to have mental health problems and are at greater risk of having suicidal thoughts.
Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.
› Verified 4 days ago
| Entity Name | University Of Pittsburgh Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619935004 PECOS PAC ID: 8729990239 Enrollment ID: O20040308000883 |
News Archive
Itamar announced today that it signed an agreement with Roche for use of Itamar's EndoPAT device in a clinical phase II study for patients with Peripheral Arterial Disease (PAD) at 80 worldwide medical centers.
According to a new study on Norwegian youth, compared to clear-skinned peers, teens who have bad acne are more than twice as likely to have mental health problems and are at greater risk of having suicidal thoughts.
Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsay Jane Mastrine, DO 2151 Menoher Blvd, Johnstown, PA 15905-1628 Ph: (315) 323-0633 | Lindsay Jane Mastrine, DO 600 Somerset Ave, Windber, PA 15963-1331 Ph: (814) 467-3176 |
News Archive
Itamar announced today that it signed an agreement with Roche for use of Itamar's EndoPAT device in a clinical phase II study for patients with Peripheral Arterial Disease (PAD) at 80 worldwide medical centers.
According to a new study on Norwegian youth, compared to clear-skinned peers, teens who have bad acne are more than twice as likely to have mental health problems and are at greater risk of having suicidal thoughts.
Salix Pharmaceuticals, Ltd. today announced that based on a telephone conversation with the U.S. Food and Drug Administration held last evening, the Company anticipates receiving a Complete Response Letter on or before the March 7, 2011 PDUFA goal date for the supplemental New Drug Application for XIFAXAN 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome and IBS-related bloating.
A new study published on the preprint server medRxiv in April 2020 suggests that an overactive immune response is responsible for the more severe manifestations of the illness.
› Verified 4 days ago
Dr. Reid Gentile, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 600 Somerset Ave, Windber, PA 15963 Phone: 814-467-3176 Fax: 814-467-3177 | |
Amy Anderson, Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 600 Somerset Ave, Windber, PA 15963 Phone: 814-467-3176 | |
Pradeep K Kulkarni, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 600 Somerset Ave, Windber, PA 15963 Phone: 814-467-3176 Fax: 814-467-3177 |